- [PRESSWIRE] Austria – 04 May, 2021 — CEBINA GmbH, an Austrian biotech company, today announces that azelastine, previously identified as a potential anti-COVID-19 drug, is equally potent against newly emerging dominant variants of SARS-CoV-2 compared to the original virus. Azelastine is available as an anti-allergy nasal spray and is currently being tested in a Phase 2 efficacy trial for the treatment of early-stage COVID-19 disease.
- [PRESSWIRE] New York, NY – Art State Productions, Inc. announces the launch of a crowdfunding campaign for Journey of Life™, an educational animated series approaching education through entertainment for the healthy emotional development of the child.
- [PRESSWIRE] Vienna, Austria – 17 February, 2021 — In the fight against the SARS-CoV-2 virus, a large number of pharmaceutical companies are looking for new approaches to combat the pandemic. In addition to vaccines, intensive research and development efforts around the world are focusing on identifying new anti-COVID therapeutics that includes re-evaluation of existing product portfolios with a view to re-purpose drugs that have antiviral properties.
- [PRESSWIRE] Madrid, Spain – 25 January, 2021 — An innovative new technology from Necenti Labs offers 96% accuracy for COVID-19 detection before infection with deep data to give companies and individuals the power of knowledge to battle lockdown.
- [PRESSWIRE] SANTA ANA, January 26, 2021 — Airionex, the leading global provider of bi-polar ionization air and surface purification technology, announced today that it has hired Françoise Parker as Senior Vice President of Sales and Marketing. Françoise will report to CEO Jukka Matikka, and will be responsible for sales team leadership, accelerating Airionex revenue throughout North America, the development and management of key channels, and overseeing the company’s marketing strategy.
- [PRESSWIRE] Germany – 21 December, 2020 — N-PATH is the most innovative European training course in interventional nephrology funded by European Commission in the framework of the Erasmus+ program coordinated by the University of Bari, in collaboration with the European Renal Association (ERA-EDTA), the Vascular Access Society, important international academic centers and two companies specialized in medical training.
- [PRESSWIRE] Austria – 19.11.20 — Eveliqure Biotechnologies GmbH, a clinical-stage biotechnology company, today announces the publication of preclinical data with ShigETEC, its vaccine candidate against Shigellae and Enterotoxic E. coli in the peer-reviewed journal Vaccines (https://doi.org/10.3390/vaccines8040689).
- [PRESSWIRE] UK – 18.11.20 — Hundreds of religious leaders from around the world gather to pray for the end of COVID-19 ahead of a group plasma donation by 4,000 Shincheonji members…
- New policy framework for digital governance calls for fundamental re-set of data regulation across telecoms and technology industries.
- [PRESSWIRE] London, UK – 21 October, 2020 — The new series of e-seminars is designed to give participants a comprehensive update on current issues and to encourage vibrant discussions. The underlying idea is to bridge the gap between research and practice by communicating and analyzing the findings from recent studies and thus to implement them in clinical practice. Another set of e-seminars will focus on the current state of the art in diagnosing and treating the various nephrological indications, which will be particularly interesting for young doctors and/or PA students.
- [PRESSWIRE] CA, US – 18 September, 2020 — Airionex announced today the results of new independent testing. Varionix® active bipolar ionization air cleaning technology from Airionex has been verified to be effective for disinfecting coronavirus from the air. The virus was completely eliminated within minutes.
- Anthemis and IA Capital Group Participate in Round; Nephila Capital and Munich Re to Provide Risk Capacity…
- [PRESSWIRE] Vienna – 30th June 2020 — Eveliqure Biotechnologies today announces that further financing has been secured from Arax Capital Partners comprising the last instalment of a €1.7M total investment provided by Arax. This is complemented by further private investment from Baobá and a Swiss based family office, and totals around €0.5M.
- [PRESSWIRE] Brussels – 2 June, 2020 — The EBRAINS shared Research Infrastructure for brain research is pleased to announce a significant step forward with the appointment of its founding CEO Paweł Świeboda. The EBRAINS digital brain research infrastructure is a key outcome of the European Commission’s Flagship 10-year research initiative Human Brain Project.
- [PRESSWIRE] Vienna – 4 June, 2020 — The Austrian biotech company CEBINA GmbH announces that it has received seed funding for its extended spectrum Coronavirus vaccine project, which is part of CEBINA’s broad-scale efforts offering short-, mid- and longer-term solutions to fight the COVID-19 pandemic. This seed funding will support proof-of-concept studies of the vaccine that will allow progress to pre-clinical development, scheduled for Q1/2021. The funds are provided by the Blom Family Office.
- [PRESSWIRE] Vienna – 2nd June 2020 — Eveliqure Biotechnologies today, announces that the Hungarian regulatory agency OGYÈI has approved the clinical trial for its vaccine program to prevent diarrhoeal diseases caused by Shigella and Enterotoxigenic E. coli (ETEC).
- [PRESSWIRE] Austria – 20 April, 2020 — Austrian biotech company Calyxha Biotechnologies GmbH is pleased to announce the grant of European Patent No. EP3383381. This patent covers the use of calixarene compounds for neurodegenerative diseases, including Parkinson’s disease. It represents the company’s first granted patent, with prosecution of the corresponding patent applications ongoing in other territories.
- [PRESSWIRE] HELSINKI – 16 April, 2020 — Karsa Oy, developer and manufacturer of chemical threat detectors for security applications, has launched a new business enterprise, Karsa Oy (Deutschland), in the Republic of Germany. Its innovative Chemical Ionization Mass Spectrometry technology was originally developed for climate change research and has been initially adapted for the detection of explosives in air cargo.
- [PRESSWIRE] Charlotte, NORTH CAROLINA – 30 March, 2020 — Over the past two weeks, the leading magazine for autism families rapidly responded to the changing needs of the autism community by providing sought after autism COVID-19 resources. Autism Parenting Magazine Editor-in-Chief Amy KD Tobik said coming together to develop tools such as social stories and visual schedules, along with professional advice, was critical.
- [PRESSWIRE] Chicago, IL United States – 19 March, 2020 — Surgisphere has developed a COVID-19 triage tool that helps prioritize care for patients who are in urgent need of care.
- [PRESSWIRE] Parma, Italy – March 12, 2020 — Kidney involvement seems to be frequent in patients who have tested positive for coronavirus. Acute kidney injury might be a predictor of mortality in infected patients.
- [PRESSWIRE] Parma – December 19, 2019 — The 2017 Annual Report of the ERA-EDTA Registry [1] reveals that only a small fraction of patients accepted for renal replacement therapy are able to start this treatment with the best available therapy, which is transplantation, – and that the number of people who are in need of renal replacement therapy is rising. This poses a major challenge to our health systems, therefore everything should be done to fight this trend, e.g. by strengthening prevention.
- [PRESSWIRE] France – 08 11 2019 -– In what represents a major milestone on the path to clinical application, a novel method to improve outcomes of Epilepsy surgery has now received approval for clinical testing in 13 French hospitals. The approach could provide a better therapeutic perspective against the drug-resistant form of the disease, which constitutes one third of all cases, and is a development by Human Brain Project scientist Viktor Jirsa and an interdisciplinary team of collaborators. To help clinicians plan surgery strategies, the scientists create personalized brain models of patients and simulate the spread of abnormal activity during epileptic seizures. The method represents the first example of a personalized brain modeling approach entering the clinic and will now be assessed over four years in a cohort of 356 patients under strict requirements.
- [PRESSWIRE] Dublin, Ireland – 09 December, 2019 — Workvivo will Provide Employee Engagement App. Irish employee engagement firm Workvivo has teamed up with US-based Seneca Gaming Corporation.
- [PRESSWIRE] Sochi, Russia – 24 October, 2019 — The Synthestech Company, has the pleasure to invite the international press and its members to a press conference entitled: A big step in the fight against aging.
- [PRESSWIRE] Squamish, B.C. – September 17, 2019 — Canadian clean energy company, Carbon Engineering Ltd. (CE), today announced it is expanding the capacity of the design for its first commercial Direct Air Capture (DAC) plant, to enable corporate customers to permanently remove carbon dioxide (CO2) emissions from the atmosphere.
- [PRESSWIRE] Budapest – June 13, 2019 — Alport syndrome (AS) is a hereditary type IV collagen disease that leads to progressive proteinuria, renal fibrosis, and kidney failure.
- [PRESSWIRE] Budapest – June 13, 2019 — High cardiovascular morbidity and mortality remain a persisting problem in patients with CKD. Many efforts have been made in subjects with normal kidney function to prevent and to reduce the progression of cardiovascular diseases.
- [PRESSWIRE] Parma – April 26, 2019 — The recently published CREDENCE study [1] showed that SGLT2 inhibitors can slow progression of chronic kidney disease (CKD) in diabetes patients in addition to the effects seen with RAAS blockade. The study results were presented at the World Nephrology Congress in Melbourne and showed that Canagliflozin was associated with a 34% risk reduction of the renal end point (end stage renal disease, doubling of serum creatinine or renal death). The previous day, the SONAR study had shown that the selective endothelin A receptor antagonist, atrasentan, reduced the risk of renal events in a specially selected CKD cohort with diabetes to a similar extent (35%).
- [PRESSWIRE] Parma – 05 March, 2019 — “Kidney health for everyone everywhere” – ERA-EDTA has helped to put this motto into practice by offering support for young nephrologists living in disadvantage areas.